Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.97 Average PT from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have received a consensus recommendation of “Buy” from the nine analysts that are covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $13.97.

Several analysts recently weighed in on VYGR shares. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, March 13th. Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Canaccord Genuity Group lowered their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th.

Voyager Therapeutics Price Performance

VYGR stock opened at $3.41 on Thursday. Voyager Therapeutics has a one year low of $3.26 and a one year high of $9.72. The stock has a market cap of $188.26 million, a price-to-earnings ratio of 4.80 and a beta of 1.02. The company has a fifty day moving average price of $4.40 and a two-hundred day moving average price of $5.59.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the previous year, the firm posted $1.25 EPS. Research analysts anticipate that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of large investors have recently modified their holdings of the business. Wellington Management Group LLP boosted its stake in Voyager Therapeutics by 13.9% in the fourth quarter. Wellington Management Group LLP now owns 261,251 shares of the company’s stock valued at $1,481,000 after buying an additional 31,882 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Voyager Therapeutics by 151.0% during the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after buying an additional 740,000 shares during the last quarter. Virtus Investment Advisers Inc. increased its holdings in shares of Voyager Therapeutics by 59.0% during the fourth quarter. Virtus Investment Advisers Inc. now owns 20,105 shares of the company’s stock worth $114,000 after buying an additional 7,457 shares in the last quarter. Tema Etfs LLC acquired a new stake in shares of Voyager Therapeutics during the 4th quarter valued at $85,000. Finally, Man Group plc acquired a new position in Voyager Therapeutics in the 4th quarter worth about $234,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.